Published in Lab Business Week, March 25th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Pharmacopeia.
Report 1: Pharmacopeia (PCOP) announced the signing of an exclusive research and license agreement with Wyeth Pharmaceuticals, a division of Wyeth (WYE). The alliance is based on Pharmacopeia's JAK3 inhibitor program and it will be focused on the research, development and commercialization of JAK3 inhibitor-based therapeutic products.
Inhibition of JAK3 has been shown in both preclinical and clinical studies to modulate disease outcomes, and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.